- Home
- SFL vs DVAX Comparison
SFL vs DVAX Comparison
Compare SFL & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- DVAX
- Stock Information
- Founded
- SFL 2003
- DVAX 1996
- Country
- SFL Bermuda
- DVAX United States
- Employees
- SFL N/A
- DVAX N/A
- Industry
- SFL Marine Transportation
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- DVAX Health Care
- Exchange
- SFL Nasdaq
- DVAX Nasdaq
- Market Cap
- SFL 1.0B
- DVAX 1.2B
- IPO Year
- SFL N/A
- DVAX 2004
- Fundamental
- Price
- SFL $7.37
- DVAX $10.15
- Analyst Decision
- SFL Strong Buy
- DVAX Buy
- Analyst Count
- SFL 1
- DVAX 4
- Target Price
- SFL $13.00
- DVAX $26.50
- AVG Volume (30 Days)
- SFL 1.2M
- DVAX 1.7M
- Earning Date
- SFL 11-05-2025
- DVAX 11-06-2025
- Dividend Yield
- SFL 14.63%
- DVAX N/A
- EPS Growth
- SFL N/A
- DVAX N/A
- EPS
- SFL 0.26
- DVAX N/A
- Revenue
- SFL $852,528,000.00
- DVAX $316,268,000.00
- Revenue This Year
- SFL N/A
- DVAX $23.23
- Revenue Next Year
- SFL $2.63
- DVAX $16.57
- P/E Ratio
- SFL $29.53
- DVAX N/A
- Revenue Growth
- SFL 3.21
- DVAX 26.66
- 52 Week Low
- SFL $6.78
- DVAX $9.20
- 52 Week High
- SFL $11.85
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- SFL 33.14
- DVAX 52.11
- Support Level
- SFL $7.49
- DVAX $9.95
- Resistance Level
- SFL $7.78
- DVAX $10.35
- Average True Range (ATR)
- SFL 0.16
- DVAX 0.29
- MACD
- SFL -0.00
- DVAX 0.08
- Stochastic Oscillator
- SFL 13.37
- DVAX 75.00
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.